• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Precipio Inc.

    1/26/26 5:08:49 PM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $PRPO alert in real time by email
    S-8 1 tm264098d1_s8.htm FORM S-8

     

    As filed with the Securities and Exchange Commission on January 26, 2026

     

    Registration No. 333-

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8

     

    REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

     

    Precipio, Inc.

    (Exact name of registrant as specified in its charter)

     

    Delaware 91-1789357
    (State or other jurisdiction of
    incorporation or organization)
    (I.R.S. Employer
    Identification No.)

     

    4 Science Park, New Haven, CT 06511
    (Address of Principal Executive Offices) (Zip Code)

     

    Precipio, Inc. Amended and Restated 2017 Stock Option and Incentive Plan

    (Full Title of the Plans)

     

    Ilan Danieli

    Chief Executive Officer

    4 Science Park,

    New Haven, CT 06511

    (Name and address of agent for service)

     

    (203) 787-7888

    (Telephone number, including area code, of agent for service)

     

    Copy to:

     

    Stephen M. Davis, Esq.

    Goodwin Procter LLP

    620 Eighth Avenue

    New York, NY

    (212) 813-8800

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ¨ Accelerated filer ¨
    Non-accelerated filer x Smaller reporting company x
      Emerging growth company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨

     

     

     

     

     

    EXPLANATORY NOTE

     

    This Registration Statement on Form S-8 (the “Registration Statement”) is being filed by Precipio, Inc. (the “Registrant”) to register additional securities issuable pursuant to the Registrant’s Amended and Restated 2017 Stock Option and Incentive Plan (the “Plan”) and consists of only those items required by General Instruction E to Form S-8. Pursuant to certain provisions of the Plan (referred to as the “evergreen provisions”), the number of shares of the Registrant’s common stock, $0.01 par value per share (the “Common Stock”), that are available for award grant purposes under the Plan, is automatically increased each year in accordance with a formula set forth in the Plan. Pursuant to the Plan’s evergreen provisions, the additional securities registered hereby include 89,045 shares of Common Stock that were automatically added to the Plan, effective January 1, 2026.

     

    In accordance with General Instruction E to Form S-8, the contents of the earlier registration statements on Form S-8 (File No. 333-284316, File No. 333-278385, File No. 333-271002, File No. 333-222819 and File No. 333-221804), as filed with the Securities and Exchange Commission (the “Commission”) on January 16, 2025, March 29, 2024, March 30, 2023, February 1, 2018 and November 29, 2017, respectively are effective and are incorporated herein by reference, except as otherwise set forth herein.

     

    Part II 

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference.

     

    The following documents have been previously filed by the Registrant with the Commission and are hereby incorporated by reference into this Registration Statement and shall be deemed a part hereof:

     

    (a)The Registrant’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Commission on March 27, 2025;

     

    (b)The Registrant’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2025, filed with the Commission on May 14, 2025;

     

    (c)The Registrant’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2025, filed with the Commission on August 13, 2025;

     

    (d)The Registrant’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2025, filed with the Commission on November 14, 2025;

     

    (e)The Registrant’s Current Reports on Form 8-K, filed with the Commission on January 21, 2025, April 10, 2025, June 17, 2025, September 3, 2025 and December 29, 2025.

     

    (f)The description of the Registrant’s Common Stock contained in the Registrant’s registration statement on Form 8-A filed with the Commission on June 29, 2017, including any amendments or reports filed for the purposes of updating this description; and

     

    All reports and other documents subsequently filed with the Commission by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934, as amended, prior to the filing of a post-effective amendment which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of filing of such documents, excluding any information furnished under Item 7.01 or Item 2.02 of any Current Report on Form 8-K (and corresponding information furnished under Item 9.01 or included as an exhibit thereto). Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for the purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document that also is or is deemed to be incorporated by reference herein modifies or replaces such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     

     

     

     

    Item 8. Exhibits.

     

    Exhibit No. Description
    3.1 Third Amended and Restated Certificate of Incorporation, as amended (incorporated by reference to Exhibit 3.1 of the Registrant’s Form 8-K filed on June 30, 2017).
    3.2 Amended and Restated Bylaws (incorporated by reference to Exhibit 3.2 of the Registrant’s Form 8-K filed on June 30, 2017).
    3.3 Certificate of Elimination (incorporated by reference to Exhibit 3.3 of the Company’s Form 8-K filed on June 30, 2017).
    3.4 Certificate of Designation for Series B Preferred Stock (incorporated by reference to Exhibit 3.1 of the Company’s Form 8-K filed on August 31, 2017).
    3.5 Certificate of Designation for Series C Preferred Stock (incorporated by reference to Exhibit 3.1 of the Company’s Form 8-K filed on November 3, 2017).
    3.6 Certificate of Amendment to the Third Amended and Restated Certificate of Incorporation, dated April 25, 2019 (incorporated by reference to Exhibit 3.1 of the Company's Form 8-K filed on April 26, 2019).
    3.7 Certificate of Amendment to the Third Amended and Restated Certificate of Incorporation, dated 21 September 21, 2023 (incorporated by reference to Exhibit 3.1 of the Company's Form 8-K filed on September 21, 2023).
    5.1* Opinion of Goodwin Procter LLP.
    23.1* Consent of Marcum LLP, Independent Registered Public Accounting Firm.
    23.2* Consent of Goodwin Procter LLP (included in Exhibit 5.1).
    24.1* Power of Attorney (included on signature page).
    99.1 Amended and Restated 2017 Stock Option and Incentive Plan (incorporated by reference to Annex B of the Registrant’s Definitive Proxy Statement on Schedule 14A filed on April 29, 2021).
    107* Filing Fee Table.

     

     

    *       Filed herewith.

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of New Haven, State of Connecticut, on the 26th day of January 2026.

     

      Precipio, Inc.
         
      By: /s/ Ilan Danieli
        Ilan Danieli
        Chief Executive Officer
    (Principal Executive Officer)

     

     

     

     

    POWER OF ATTORNEY AND SIGNATURES

     

    KNOW ALL BY THESE PRESENT, that each individual whose signature appears below hereby constitutes and appoints each of Ilan Danieli and Matthew Gage as such person’s true and lawful attorney-in-fact and agent with full power of substitution and resubstitution, for such person in such person’s name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8, and to file the same, with all exhibits thereto, and all documents in connection therewith, with the Securities and Exchange Commission granting unto each said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that any said attorney-in-fact and agent, or any substitute or substitutes of any of them, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following person in the capacities and on the date indicated.

     

    Signature Title Date
    /s/ Ilan Danieli

    Director and Chief Executive Officer

    (Principal Executive Officer)

    January 26, 2026
    Ilan Danieli

     

    /s/ Matthew Gage

     

    Interim Chief Financial Officer

    (Principal Financial and Accounting Officer)

    January 26, 2026
    Matthew Gage

     

    /s/ Richard Sandberg

     

    Chairman of the Board of Directors

    January 26, 2026
    Richard Sandberg

     

    /s/ Kathleen Laporte

    Director January 26, 2026

    Kathleen Laporte

     

    /s/ Ronald Andrews

    Director January 26, 2026
    Ronald Andrews

     

    /s/ Christina Valauri.

    Director January 26, 2026
    Christina Valuari

     

    /s/ Jeffrey Cossman, M.D.

    Director January 26, 2026
    Jeffrey Cossman, M.D.

     

    /s/ David Cohen

    Director January 26, 2026
    David Cohen

     

     

     

    Get the next $PRPO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PRPO

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PRPO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Precipio Takes Major Steps Toward a Clean Balance Sheet

    NEW HAVEN, Conn., Jan. 15, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO) has made major strides in cleaning up its balance sheet with two major accomplishments: 1. Major obligation repaid A $1.1 million advance from Change Healthcare ("CHC"), the Company's clearinghouse service for billing claims processing, has been repaid. CHC experienced a cybersecurity incident in 2024 and advanced Precipio and others funds to cover collections shortfalls. In early January 2026, the Company completed its repayment of that advance. Precipio maintains a small loan with the Connecticut Department of Economic and Community Development in the approximate princ

    1/15/26 9:00:00 AM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Precipio to Showcase its BCR::ABL1 panel at 2025 ASH (American Society of Hematology) Meeting

    NEW HAVEN, Conn., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO) will be presenting at ASH the findings of a joint study conducted with scientific collaborators from Memorial Sloan Kettering in New York, evaluating Precipio's BCR::ABL1 assay. The data from a comprehensive study includes 895 patient samples and demonstrates superior performance of the assay, while showing concordance with two other leading platforms. The study shows clear, positive impacts on patient care alongside substantial improvements in laboratory workflows. Poster presentation of the study abstract, and results discussion are scheduled for Monday December 8th fro

    12/5/25 10:00:00 AM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Precipio Identifies Unauthorized Access to Isolated Storage; No Operational Impact

    NEW HAVEN, Conn., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Precipio, Inc. reports that the Company recently identified a single, limited scope unauthorized access to a specific data folder stored within its secure cloud file environment. The incident was limited to its file storage server and did not impact any of Precipio's operations, diagnostics processes, or customer services, and the company continued to provide its services unhindered. There was no impact to patient care; nor impact to the company's operations or finances. Upon detecting the activity, the Company immediately initiated its incident response procedures and engaged an external cybersecurity law firm and forensic specialists t

    12/4/25 8:00:00 AM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $PRPO
    SEC Filings

    View All

    SEC Form S-8 filed by Precipio Inc.

    S-8 - Precipio, Inc. (0001043961) (Filer)

    1/26/26 5:08:49 PM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Precipio Inc. filed SEC Form 8-K: Leadership Update

    8-K - Precipio, Inc. (0001043961) (Filer)

    12/29/25 5:00:27 PM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 10-Q filed by Precipio Inc.

    10-Q - Precipio, Inc. (0001043961) (Filer)

    11/14/25 4:29:52 PM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $PRPO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Chief Operating Officer Sabet Ahmed Zaki bought $468 worth of shares (20 units at $23.40), increasing direct ownership by 2% to 1,015 units (SEC Form 4)

    4/A - Precipio, Inc. (0001043961) (Issuer)

    1/20/26 4:22:27 PM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: Chief Operating Officer Sabet Ahmed Zaki bought $488 worth of shares (25 units at $19.50), increasing direct ownership by 3% to 995 units (SEC Form 4)

    4/A - Precipio, Inc. (0001043961) (Issuer)

    1/20/26 4:21:46 PM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: Chief Operating Officer Sabet Ahmed Zaki bought $505 worth of shares (31 units at $16.30), increasing direct ownership by 3% to 970 units (SEC Form 4)

    4/A - Precipio, Inc. (0001043961) (Issuer)

    1/20/26 4:19:49 PM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $PRPO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Director Andrews Ronald Asbury was granted 568 shares, increasing direct ownership by 4% to 15,796 units (SEC Form 4)

    4/A - Precipio, Inc. (0001043961) (Issuer)

    1/20/26 4:25:16 PM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: Director Cohen David Seth was granted 746 shares, increasing direct ownership by 1% to 53,688 units (SEC Form 4)

    4/A - Precipio, Inc. (0001043961) (Issuer)

    1/20/26 4:24:23 PM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: Director Cossman Jeffrey was granted 597 shares, increasing direct ownership by 4% to 15,340 units (SEC Form 4)

    4/A - Precipio, Inc. (0001043961) (Issuer)

    1/20/26 4:23:26 PM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $PRPO
    Leadership Updates

    Live Leadership Updates

    View All

    Precipio Inc. Announces the Resignation of its Chief Financial Officer and Appointment of Interim CFO

    NEW HAVEN, Conn., March 21, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), today announced that Mr. Carl Iberger, Precipio's CFO for the past five years, is resigning as the Chief Financial Officer effective as of today, March 21st, 2022. Mr. Iberger wishes to spend more time with his family and therefore has made the decision to step down from his role as CFO. Matt Gage, who currently serves as Director of Financial Reporting and Analysis has been promoted to Interim Chief Financial Officer of the Company effective immediately. Mr. Gage joined Precipio following its acquisition of Transgenomic in July of 2017. He has worked closely with Mr. Ib

    3/21/22 5:00:00 PM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    89bio Announces Appointment of Kathy LaPorte to its Board of Directors

    SAN FRANCISCO, Nov. 03, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced the appointment of Kathy LaPorte to its Board of Directors, effective immediately. Ms. LaPorte brings deep expertise and valuable experience in the industry to the Company. "It is a pleasure to welcome Kathy, an esteemed industry leader, to our Board of Directors," said Rohan Palekar, Chief Executive Officer of 89bio. "Kathy has a strong track record for enhancing operational capabilities to drive growth. Her extensive experien

    11/3/21 8:00:00 AM ET
    $BOLT
    $ETNB
    $PRPO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Mr. Richard Sandberg is appointed Chairman of Precipio’s Board of Directors

    NEW HAVEN, Conn., March 03, 2021 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces the appointment of Mr. Richard Sandberg as Chairman of the Board of Directors. Dr. Douglas Fisher will step down as Chairman and maintain his role as a Director on the company’s board. Mr. Sandberg has been involved with Precipio since its inception and has acted in various advisory roles. in 2019 he joined the company’s Board of Directors and has been a significant contributor to helping the company formulate strategy and execute on its plans. Mr Sandberg is a seasoned diagnostics executive with a substantial track record in the field of diagnostics. As the f

    3/3/21 11:00:00 AM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $PRPO
    Financials

    Live finance-specific insights

    View All

    Precipio Takes Major Steps Toward a Clean Balance Sheet

    NEW HAVEN, Conn., Jan. 15, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO) has made major strides in cleaning up its balance sheet with two major accomplishments: 1. Major obligation repaid A $1.1 million advance from Change Healthcare ("CHC"), the Company's clearinghouse service for billing claims processing, has been repaid. CHC experienced a cybersecurity incident in 2024 and advanced Precipio and others funds to cover collections shortfalls. In early January 2026, the Company completed its repayment of that advance. Precipio maintains a small loan with the Connecticut Department of Economic and Community Development in the approximate princ

    1/15/26 9:00:00 AM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Precipio to Showcase its BCR::ABL1 panel at 2025 ASH (American Society of Hematology) Meeting

    NEW HAVEN, Conn., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO) will be presenting at ASH the findings of a joint study conducted with scientific collaborators from Memorial Sloan Kettering in New York, evaluating Precipio's BCR::ABL1 assay. The data from a comprehensive study includes 895 patient samples and demonstrates superior performance of the assay, while showing concordance with two other leading platforms. The study shows clear, positive impacts on patient care alongside substantial improvements in laboratory workflows. Poster presentation of the study abstract, and results discussion are scheduled for Monday December 8th fro

    12/5/25 10:00:00 AM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Precipio Identifies Unauthorized Access to Isolated Storage; No Operational Impact

    NEW HAVEN, Conn., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Precipio, Inc. reports that the Company recently identified a single, limited scope unauthorized access to a specific data folder stored within its secure cloud file environment. The incident was limited to its file storage server and did not impact any of Precipio's operations, diagnostics processes, or customer services, and the company continued to provide its services unhindered. There was no impact to patient care; nor impact to the company's operations or finances. Upon detecting the activity, the Company immediately initiated its incident response procedures and engaged an external cybersecurity law firm and forensic specialists t

    12/4/25 8:00:00 AM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $PRPO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Precipio Inc.

    SC 13G - Precipio, Inc. (0001043961) (Subject)

    8/2/24 2:15:53 PM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials